



Bilcare and MeadWestvaco jointly acquired International Labs Inc., USA, an integrated drug packaging company

The focus of this venture is to work with retailers, including Wal-Mart, and generic and branded pharmaceutical companies to bring innovative healthcare compliance and technology solutions to meet the dynamic challenges of the US healthcare sector.

- DMF regd. with USFDA
- EEC / USP
- Member, IQA, London
- OPPI Award Winner
- Pioneer Status from Govt. of Singapore
- ISO 9001:2000 & 14001:2004 Company

Bilcare, a unique organization with a strong research foundation and an unending quest for global leadership. An organization, integrated with global Pharmaceuticals having best in class manufacturing and research facilities spread worldwide. An organization made up of motivated people who go that extra mile to spread excellence and joy.

Bilcare Limited - Regd. Office : 1028, Shirol, Pune 410 505.

Unaudited Financial Results for the quarter ended 30th June, 2008

(Rs. in Crores)

Sr. No.	Particulars	Quarter Ended 30/06/2008 (Unaudited)	Corresponding Quarter Ended 30/06/2007 (Unaudited)	Previous Year ended 31/03/2008 (Audited)	Consolidated Quarter Ended 30/06/2008 (Unaudited)	Corresponding Consolidated Quarter Ended 30/06/2007 (Unaudited)	Consolidated Previous Year ended 31/03/2008 (Audited)
1.	Net Sales/Income from Operations	113.76	92.88	406.35	187.50	130.83	650.68
2.	Other Income	0.07	0.82	15.77	0.07	1.03	19.24
3.	Total Income (1+2)	113.83	93.70	422.12	187.57	131.86	669.92
4.	Expenditure						
a.	(Increase)/decrease in stock in trade and work in progress	(1.17)	(12.02)	(8.06)	(1.85)	(13.50)	(6.41)
b.	Consumption of Raw Materials	69.47	66.65	247.57	100.03	86.09	361.50
c.	Employees Cost	4.64	3.79	15.64	15.41	9.36	60.55
d.	Depreciation	4.32	3.55	15.71	7.48	5.05	24.16
e.	Other Expenditure	8.68	8.45	38.29	28.26	17.87	91.57
f.	Total	85.94	70.42	309.15	149.33	104.87	531.37
5.	Interest	3.52	2.77	11.44	8.10	3.11	14.27
6.	Profit from Ordinary Activities before Tax (3) - (4+5)	24.37	20.51	101.53	30.14	23.88	124.28
7.	Tax Expense	8.28	6.97	39.84	9.06	7.35	42.73
8.	Net Profit from Ordinary Activities after Tax (6-7)	16.09	13.54	61.69	21.08	16.53	81.55
9.	Paid-up Equity Share Capital (face value Rs.10/- each)	17.21	15.09	16.45			16.45
10.	Reserves excluding Revaluation Reserves	---	---	346.79			372.39
11.	Earnings Per Share for the Period (Rs.)						
a.	Basic	9.35	8.97	37.49			
b.	Diluted	8.38	8.16	32.14			
12.	Public Shareholding						
-	No. of Shares	9,176,791	8,512,526	9,176,791			
-	Percentage of Shareholding	53.33%	56.40%	55.78%			

Notes:

1. The Company's main business segment is pharma packaging research solutions.
2. The Company had received 1 investor complaint during the quarter, which was redressed and there were no investor complaints pending for redressal at the commencement and at the end of the quarter.
3. The Company has, during the quarter allotted 755,000 Equity Shares of Rs.10/- each at Rs.535 per share, including premium, upon conversion of Warrant 'B' issued to the promoters. Consequently, the Paid-up Equity Share Capital of the Company stands increased to Rs. 172,080,650/-
4. During July 2008, the Company along with MeadWestvaco acquired International Labs Inc., USA.
5. The previous year's figures have been regrouped / readjusted wherever necessary.
6. The above unaudited Financial Results were approved by the Board of Directors of the Company at its meeting held on 29th July, 2008.

For Bilcare Limited

Mohan H. Bhandari
Managing Director